ClinicalTrials.gg
Active, not recruitingNCT05008588Updated Feb 25, 2026

Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct

A Phase 1/2 interventional study of Conditioned Medium and Umbilical Cord Mesenchymal Stem Cells in Ischemic Stroke, sponsored by PT. Prodia Stem Cell Indonesia. Active, not recruiting at 2 sites in Indonesia. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by PT. Prodia Stem Cell Indonesia · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Ischemic Stroke with a site in Indonesia — 3 open to participants now, 4 under way, 1 of them phase 3. Ischemic Stroke · Indonesia.

Planned enrollment
9th of 10
15 · median 75
Started
2022
the only one that year
Phase 1/2
Only one
of the 10
Registered
6th of 10
by date
Lead sponsor
1 of 10
PT. Prodia Stem Cell Indonesia

Among the 10 studies in Ischemic Stroke with a site in Indonesia, this one is the 9th largest by planned enrollment, is the only one that started in 2022, is the only one in phase 1/2, and was the 6th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

3 of the 10 studies in Ischemic Stroke with a site in Indonesia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 25 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Ischemic Stroke with a site in Indonesia, or all of them as a file.
02

Study summary

The purpose of this study was to determine the effectiveness of a combination of intranasal conditioned medium (CM) with intraparenchymal umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in acute stroke patients to induce neurogenesis.

Read the detailed description

This study has 3 arms namely CM and UC-MSCs treatment, UC-MSCs treatment only, and control. The investigator hypothesized that group of CM and UC-MSCs combination is the optimal treatment to induce neurogenesis in stroke patients.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

Keywords

  • Ischemic stroke
  • Mesenchymal Stem Cells
  • Conditioned Medium
  • Secretome
04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 25-60 years diagnosed with ischemic stroke acute phase
  • The patient has had a CT scan/MRI of the brain to assess ischemic territory
  • The patient must have an NIH Stroke score of 8-20
  • The patient or legal assistant has obtained detailed regarding the study protocol and agreeing to participate in the study
  • Patients with The Glasgow Coma Scale (GCS) score > 8
  • Patients with Pt- values within normal limits

Exclusion criteria

Exclusion Criteria:

  • Patients with recurrent stroke in the 6 months preceding the episode current stroke
  • CT or MRI images show midline shift and bleeding transformation
  • Participate in similar studies using CM and/or UC-MSC
  • Patients who are and/or who are receiving therapy immunosuppressive
  • Patients who cannot have a CT or MRI examination due to their condition
  • Patients with impaired renal and hepatic function after the onset of ischemic stroke: Serum Glutamic Oxaloacetic Transaminase () and Serum Glutamic Pyruvic Transaminase (SGPT) > 5x the values and a significant increase in urea-creatinine values
  • Patients with a history of malignant tumors or other severe neurologic conditions.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment

    Intranasal of 3 cc of conditioned medium each, for 3 days in a row and Intra-parenchymal transplantation of 20x10\^6 UC-MSCs

    Biological: Conditioned Medium · Biological: Umbilical Cord Mesenchymal Stem Cells

  • Experimental
    Umbilical cord mesenchymal stem cells treatment

    Intra-parenchymal transplantation of 20x10\^6 UC-MSCs

    Biological: Umbilical Cord Mesenchymal Stem Cells

  • Active comparator
    Standard treatment (control)

    Neurologic and Neutrophic Drugs

    Procedure: Neurologic and Neutrophic Drugs

Interventions

  • BiologicalConditioned Medium

    Intranasal of 3 cc of conditioned medium each, for 3 days in a row

    Also known as: Secretome

  • Intra-parenchymal transplantation of 20x10\^6 UC-MSCs

    Also known as: Mesenchymal stromal cells

  • ProcedureNeurologic and Neutrophic Drugs

    Such as clopidogrel, piracetam, citicoline

06

What researchers measure

Primary outcomes

  1. Change from baseline Brain-Derived Neutrophic Factor at one month, 3 months and 6 months after transplantation

    Venous blood collection

    Time frame: Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment

  2. Change from baseline Vascular endothelial growth factor at one month, 3 months and 6 months after transplantation

    Venous blood collection

    Time frame: Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment

  3. Change baseline Magnetic Resonance Imaging at 6 month after transplantation

    To observe the brain development (neurogenesis)

    Time frame: Before treatment, 6 month after transplantation

Secondary outcomes

  1. The National Institute of Health Stroke Scale (NIHSS) Scoring

    The NIH Stroke Scale (NIHSS) is a 15-item scale that is a well-validated and prognostically important measure of stroke-related neurologic deficits in research and clinical care

    Time frame: Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment

  2. modified Rankin Scale (mRS)

    The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke

    Time frame: Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment

07

Study locations

2 sites
  • Gatot Soebroto Hospital
    Jakarta Pusat, DKI Jakarta 10410, Indonesia
  • PT Prodia StemCell Indonesia
    Jakarta, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Mar 2026, 46 months after the start.

Of 27 phase 1/2 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2021
First posted
Aug 17, 2021
StartActual
May 30, 2022
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05008588
Lead sponsor
PT. Prodia Stem Cell Indonesia
Responsible party
Sponsor
First posted
Aug 17, 2021
Start date
May 30, 2022
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Feb 25, 2026

Study contacts

Rima Haifa
principal investigator · Prodia StemCell Indonesia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion